There have been significant advances in the management of patients with advanced genitourinary malignancies in the last decade. These advances mostly affect prostate cancer, bladder cancer and renal cell carcinoma. For these patients, survival could be significantly improved by the introduction of new drugs including androgen-pathway targeting drugs for prostate cancer, immunotherapy and other targeted drugs (such as FGFR inhibitors and antibody drug conjugates) for urothelial carcinoma and immunotherapy combinations for renal cell carcinoma.
Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review
KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging—utilization of a short-pass filter to reduce technical pitfalls
ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis
Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer
Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review
Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review
Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review
Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature
Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
The series “Management of Advanced Genitourinary Malignancies” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding. Tilman Todenhöfer served as the unpaid Guest Editor for the series.